Clarity’s copper platform, strong prostate pipeline and therapeutic and diagnostic efficacy data represent an attractive opportunity to grow a significant radiopharmaceutical franchise in oncology.
What is covered in the Full Insight:
FDA Fast Track Designation
Clinical and Financial Milestones
Comparative Advantage of 64Cu-SAR-bisPSMA
Market Opportunity in Prostate Cancer
Radiopharmaceutical Industry Acquisitions
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.